WO2009030093A1 - Fonctions et utilisations de l'inhibiteur 2 de la protéine phosphatase 1 humaine - Google Patents

Fonctions et utilisations de l'inhibiteur 2 de la protéine phosphatase 1 humaine Download PDF

Info

Publication number
WO2009030093A1
WO2009030093A1 PCT/CN2007/070638 CN2007070638W WO2009030093A1 WO 2009030093 A1 WO2009030093 A1 WO 2009030093A1 CN 2007070638 W CN2007070638 W CN 2007070638W WO 2009030093 A1 WO2009030093 A1 WO 2009030093A1
Authority
WO
WIPO (PCT)
Prior art keywords
ipp2
human
phosphatase inhibitor
human phosphatase
expression
Prior art date
Application number
PCT/CN2007/070638
Other languages
English (en)
Chinese (zh)
Inventor
Xiaojian Wang
Nan Li
Xuetao Cao
Original Assignee
Zhejiang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University filed Critical Zhejiang University
Priority to PCT/CN2007/070638 priority Critical patent/WO2009030093A1/fr
Publication of WO2009030093A1 publication Critical patent/WO2009030093A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • the present invention is in the field of biotechnology and medicine, and in particular, the present invention relates to a novel use of a human phosphatase inhibitor IPP2 polypeptide. Background technique
  • Type 1 protein phosphatase (PP-1) is a very important class of serine/threonine phosphatases that regulate the cell cycle by dephosphorylation of proteins. Physiological functions such as gene expression, protein synthesis, glycolipid metabolism, and memory formation. It consists of a catalytic subunit and a regulatory subunit that determines the substrate specificity, activity, and subcellular localization of the phosphatase.
  • IPP-1 protein phosphatase 1
  • pCREB cAMP response element binding protein
  • Phosphorylation-related factors have important physiological functions. Therefore, there is an urgent need in the art to develop new phosphorylation-related factors and to study the functions of these factors in order to provide effective targets for drug development. Purpose of the invention
  • the object of the present invention is to provide a novel human bone marrow stromal cell-derived type 1 phosphatase inhibitor
  • IPP2 protein as well as fragments, analogs and derivatives thereof.
  • Another object of the invention is to provide polynucleotides encoding these polypeptides.
  • Another object of the invention is to provide methods and uses for the production of these polypeptides.
  • a human phosphatase inhibitor IPP2 or a gene encoding the same or an agonist thereof for the preparation of a composition for inhibiting the production of inflammatory cytokines.
  • the inflammatory cytokine is selected from the group consisting of: interleukin-6 (IL-6), or tumor necrosis factor a (TNF) 0
  • the inflammatory cytokine is induced by lipopolysaccharide endotoxin (LPS).
  • LPS lipopolysaccharide endotoxin
  • the composition is also useful for inhibiting apoptosis.
  • the apoptosis is induced by NO.
  • the human phosphatase inhibitor IPP2 is selected from the group consisting of:
  • a protein derived from (1) which is formed by substitution, deletion or addition of the amino acid sequence of SEQ ID NO: 2 by one or more amino acid residues, and which has an IL-6-producing function.
  • the composition is a pharmaceutical composition.
  • a method of screening for a potential substance that inhibits an inflammatory cytokine comprising:
  • step (a) comprises: adding a candidate substance to the system containing the human phosphatase inhibitor IPP2 in the test group; and/or
  • Step (b) comprises: detecting the expression or activity of the human phosphatase inhibitor IPP2 in the system of the test group, and comparing the control group with the human phosphatase inhibitor IPP2 without adding the candidate substance System
  • the control group is indicated to be a potential substance that inhibits inflammatory cytokines.
  • the method further includes the steps of:
  • system is a cellular system.
  • the invention provides a method of inhibiting inflammatory cytokines in vitro (therapeutic or non-therapeutic) or in vivo, the method comprising: increasing expression or activity of a human phosphatase inhibitor IPP2 in a cell.
  • Figure 1 shows the human IPP2 RT-PCR expression analysis of the present invention, suggesting that IPP2 is expressed in certain tumor cells; wherein, Figure 1A and Figure 1B are expressions in subcultured tumor cell lines; Figure 1C is in normal humans. Expression in different parts of the fetal brain.
  • FIG 2 shows the distribution shown by human IPP2 Northern blot hybridization of the present invention. The results suggest that IPP2 is a molecule with a specific tissue distribution; Figure 2A shows the distribution in normal adult tissues; Figure 2B shows the distribution in normal fetal tissues.
  • Figure 3 shows the inhibitory effect of human IPP2 on NO-induced apoptosis in RAW 264.7 cells.
  • FIG. 4 shows that human IPP2 inhibits LPS-stimulated RAW264.7 cells producing cytokines TNF ( ⁇ ) and IL-6 (B).
  • the human phosphatase inhibitor IPP2 (pr 0 tein phosphatase 1 inhibitor-2) has the function of inhibiting inflammatory factors such as interleukin-6 or tumor necrosis factor alpha. Significant inhibition of the production of intracellular inflammatory factors. Therefore, the human phosphatase inhibitor ⁇ 2 itself can be used for the preparation of a composition for inhibiting inflammatory factors, or the human phosphatase inhibitor ⁇ 2 can be used as a target for drug screening for screening for substances which inhibit inflammatory factors by promoting their activity. . The present invention has been completed on this basis.
  • the inventors' studies have shown that the human phosphatase inhibitor ⁇ 2 is expressed in some hematopoietic tumors such as Daudi, MOLT-4, Raji, THP-K K562, HT-29, Hela, A549, NAM, TF. There were different degrees of expression in -1, 2162, Hut, and Hela, A549, and HT29 solid tumors.
  • Northern blotting revealed that IPP2 mRNA is specifically expressed in the heart, liver, skeletal muscle, and testis of normal humans, with three transcripts in the myocardium and skeletal muscle. The molecule was confirmed to inhibit PP-1 enzyme activity by in vitro kinase assay, and the IC50 was similar to the human IPP-1 protein.
  • IPP2 inhibits LPS-induced ERK1/2 activation and inhibits NO-induced RAW 264.7 apoptosis.
  • Transiently transfected NIH 3T3 and PC-12 cells with IPP2 maintained a high level of CREB phosphorylation by 8-Br-cAMP/IBMX. Phosphorylation of CREB can increase the expression of the anti-apoptotic protein Bcl-2.
  • the present inventors screened a cell line stably expressing RAW264.7 of IPP2 and the mutant and confirmed that RAW264.7 cells overexpressing IPP2, shI-2, and shl-1 were able to resist NO-induced apoptosis.
  • IPP2 can It inhibits NO-induced caspase-3 activation, decreased Bcl-2 and Bcl-xl protein levels.
  • IPP2 is significantly more effective than shI-2, shl-l.
  • IPP2 inhibition was not obvious.
  • IPP2 could not inhibit LPS/IFN ⁇ -induced caspase-3 activation, Bcl-2 and Bcl-xl protein levels.
  • the inactivating mutant (; CA) does not have the above functions, suggesting that the above functions of IPP2 are related to its inhibition of PP 1 enzyme activity.
  • IPP2 acts as a novel phosphatase inhibitor, by inhibiting phosphatase, maintaining the phosphorylation of certain important signaling pathway mediators or transcription factors, transmitting and amplifying certain signals, in anti-apoptosis, anti-infection, etc.
  • the aspect plays an important role, so the molecule has important development and application value.
  • IPP2 can be used to prepare a composition that inhibits the production of inflammatory cytokines or to screen for substances that inhibit inflammatory cytokines.
  • cells are infected with inflammatory cytokines such as IL-6 or TNF ci after infection (such as endotoxin-induced infection), thereby inhibiting the production or activity of inflammatory cytokines to inhibit the occurrence or development of inflammation. .
  • IPP2 can also be used to inhibit apoptosis, for example, when IPP2 is contacted with NO-induced cells, the proportion of apoptosis of the cells can be greatly reduced.
  • Human phosphatase inhibitor IPP2 Human phosphatase inhibitor IPP2
  • IPP2 protein is used interchangeably and refer to type 1 phosphatase inhibitors derived from human bone marrow stromal cells.
  • a protein or polypeptide of the IPP2 amino acid sequence (SEQ ID NO: 2).
  • isolated means that the substance is separated from its original environment (if it is a natural substance, the original environment is the natural environment).
  • the polynucleotides and polypeptides in the natural state in living cells are not isolated and purified, but the same polynucleotide or polypeptide is separated and purified, such as from other substances existing in the natural state. .
  • isolated IPP2 protein or polypeptide means that the IPP2 polypeptide is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. Those skilled in the art will be able to purify the IPP2 protein using standard protein purification techniques. A substantially pure polypeptide produces a single major band on a non-reducing polyacrylamide gel.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, a synthetic polypeptide, preferably a recombinant polypeptide.
  • the polypeptide of the present invention may be a naturally purified product, or a chemically synthesized product, or may be regenerated from the pronuclear using a recombinant technique. Or produced in eukaryotic hosts (eg, bacteria, yeast, higher plants, insects, and mammalian cells).
  • the polypeptide of the invention may be glycosylated, or may be non-glycosylated, depending on the host used in the recombinant production protocol. Polypeptides of the invention may also or may not include an initial methionine residue.
  • the invention also includes fragments, derivatives and analogs of the human IPP2 protein.
  • fragment refers to a polypeptide that substantially retains the same biological function or activity of the native human IPP2 protein of the present invention.
  • the polypeptide fragment, derivative or analog of the present invention may be (i) a polypeptide having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues It may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent group in one or more amino acid residues, or (iii) a mature polypeptide and another compound (such as a compound that extends the half-life of the polypeptide, for example a polypeptide formed by fusion of a polyethylene glycol) or (iv) an additional amino acid sequence fused to the polypeptide sequence (eg, a leader or secretion sequence or a sequence or proprotein sequence used to purify the polypeptide, or A fusion protein for the formation of an antigenic IgG fragment).
  • conservative amino acid residues preferably conservative amino acid residues
  • human IPP2 polypeptide refers to a polypeptide having the sequence of SEQ ID NO. 2 of human IPP2 protein activity.
  • the term also encompasses variant forms of the sequence of SEQ ID NO. 2 that have the same function as the human IPP2 protein. These variants include, but are not limited to, a number (usually 1-50, preferably 1-30, more preferably 1-20, optimally 1-10) amino acid deletions, insertions And/or substitution, and addition of one or several (usually within 20, preferably within 10, more preferably within 5) amino acids at the C-terminus and/or N-terminus.
  • the function of the protein is usually not altered.
  • the addition of one or more amino acids at the C-terminus and/or N-terminus will generally not alter the function of the protein.
  • the term also encompasses active fragments and active derivatives of the human IPP2 protein.
  • Variants of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that hybridize to human IPP2 DNA under high or low stringency conditions And a polypeptide or protein obtained by using an antiserum against the human IPP2 polypeptide.
  • the invention also provides other polypeptides, such as fusion proteins comprising a human IPP2 polypeptide or a fragment thereof. In addition to the nearly full length polypeptide, the present invention also encompasses soluble fragments of the human IPP2 polypeptide.
  • the fragment has at least about 10 contiguous amino acids of the human IPP2 polypeptide sequence, typically at least about 30 contiguous amino acids, preferably at least about 50 contiguous amino acids, more preferably at least about 80 contiguous amino acids, optimally at least about 100 consecutive amino acids.
  • the invention also provides analogs of human IPP2 proteins or polypeptides.
  • the difference between these analogs and the natural human IPP2 polypeptide may be a difference in amino acid sequence, or may be a difference in the modification form that does not affect the sequence, or Both have both.
  • the "human IPP2 protein conservative variant polypeptide” means up to 10, preferably up to 8, more preferably up to 5, most preferably up to the amino acid sequence of SEQ ID NO: 2.
  • the three amino acids are replaced by amino acids of similar or similar nature to form a polypeptide.
  • the polynucleotide of the present invention may be in the form of DNA or RNA.
  • DNA forms include cDNA, genomic DNA or synthetic DNA.
  • DNA can be single-stranded or double-stranded.
  • the DNA can be a coding strand or a non-coding strand.
  • the coding region sequence encoding the mature polypeptide may be the same as or the degenerate variant of the coding region shown in SEQ ID NO: 1.
  • a "degenerate variant" in the present invention refers to a nucleic acid sequence which encodes a protein having SEQ ID NO: 2 but differs from the coding region sequence set forth in SEQ ID NO: 1.
  • Polynucleotides encoding the mature polypeptide of SEQ ID NO: 2 include: a coding sequence encoding only the mature polypeptide; a coding sequence for the mature polypeptide and various additional coding sequences; a coding sequence for the mature polypeptide (and optionally additional coding sequences) and Non-coding sequence.
  • polynucleotide encoding a polypeptide may be a polynucleotide comprising the polypeptide, or may be a polynucleotide further comprising additional coding and/or non-coding sequences.
  • the present invention also relates to variants of the above polynucleotides which encode fragments, analogs and derivatives of polypeptides or polypeptides having the same amino acid sequence as the present invention.
  • Variants of this polynucleotide may be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants.
  • an allelic variant is an alternative form of a polynucleotide which may be a substitution, deletion or insertion of one or more nucleotides, but does not substantially alter the function of the polypeptide encoded thereby. .
  • the invention also relates to polynucleotides which hybridize to the sequences described above and which have at least 50%, preferably at least 70%, more preferably at least 80% identity between the two sequences.
  • the invention particularly relates to polynucleotides that hybridize to the polynucleotides of the invention under stringent conditions.
  • stringent conditions means: (1) hybridization and elution at a lower ionic strength and a higher temperature, such as 0.2 X SSC, 0.1% SDS, 60 ° C ; or 2) Hybridization is carried out with a denaturing agent such as 50% (v/v) formamide, 0.1% calf serum/0.1% Ficol l, 42 °C, etc.; or (3) only in two sequences Hybridization occurs when the identity is at least 90% or more, more preferably 95% or more.
  • the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide represented by SEQ ID NO: 2. Antagonists or agonists of IPP2 and uses thereof
  • the invention also relates to antagonists and agonists of IPP2.
  • an antagonist of IPP2 refers to a substance that is capable of combating, or reducing, the activity or expression of an IPP2 polypeptide.
  • Common antagonists are antibodies, antisense nucleotides, and interfering RNA (RNAi).
  • RNAi interfering RNA
  • the antagonist can be used to alleviate the inhibitory effect of IPP2 on the production of inflammatory cytokines (e.g., IL-6 or TNF-o).
  • an agonist of IPP2 refers to any substance that increases the activity of IPP2, maintains the stability of IPP2, promotes IPP2 expression, prolongs the effective duration of IPP2, or promotes transcription and translation of IPP2. These substances can be used to potentiate the inhibitory effects of IPP2 on the production of inflammatory cytokines (such as IL-6 or TNF-o. Screening for substances that inhibit inflammatory cytokines)
  • the present invention provides a method of screening for potential substances that inhibit inflammatory cytokines, comprising the steps of:
  • the candidate substance is contacted with a system containing IPP2; the effect of the candidate substance on the expression or activity of IPP2 is observed; wherein, if the candidate substance can increase the expression or activity of IPP2, it indicates that the candidate substance is a potential for inhibiting inflammatory cytokine substance.
  • the system is selected from, but not limited to, a solution system, a cell system, a subcellular system, a tissue system, an organ system, or an animal system.
  • a control group in order to make it easier to observe changes in IPP2, a control group may be provided, and the control group may be an IPP2-containing system to which the candidate substance is not added.
  • These initially screened materials can form a screening library for further cellular and/or animal testing of these materials so that they can ultimately be screened for drugs that are truly useful for inhibiting inflammatory cytokines.
  • the present invention also includes a class of substances which inhibit inflammatory cytokines obtained by the screening method of the present invention, which act on IPP2, improve the activity of IPP2, maintain the stability of IPP2, promote the expression of IPP2, and prolong the effective effect of IPP2. Time, or promote the transcription and translation of IPP2 to play a role in inhibiting inflammatory cytokines.
  • Compositions and methods of treatment which act on IPP2, improve the activity of IPP2, maintain the stability of IPP2, promote the expression of IPP2, and prolong the effective effect of IPP2. Time, or promote the transcription and translation of IPP2 to play a role in inhibiting inflammatory cytokines.
  • the present invention also provides a composition
  • a composition comprising an effective amount (such as 0.00001-0.01 g / 60 kg body weight / day; preferably, 0.0001 - 0.005 g / 60 kg body weight / day) of the IPP2 protein, Or an agonist of IPP2, and a pharmaceutically or food acceptable carrier.
  • a "pharmaceutically or foodly acceptable” ingredient is suitable for use in humans and/or mammals without excessive adverse side effects (eg, toxicity, irritation, and allergies), ie, has reasonable benefits/ The substance of the risk ratio.
  • pharmaceutically acceptable carrier refers to a carrier for the administration of a therapeutic agent, including various excipients and diluents.
  • the term refers to pharmaceutical carriers which are not themselves essential active ingredients and which are not excessively toxic after administration. Suitable carriers are well known to those of ordinary skill in the art.
  • the pharmaceutically acceptable carrier in the composition may contain a liquid such as water, saline, glycerin and ethanol.
  • auxiliary substances such as lubricants, glidants, wetting or emulsifying agents, pH buffering substances and the like may also be present in these carriers.
  • the invention also provides a method of inhibiting an inflammatory cytokine comprising administering to the subject an effective amount of an IPP2 protein, or an agonist of IPP2.
  • the effective dose of IPP2 or its agonist used may vary with the severity of the subject to be treated. The specific circumstances are determined by the individual circumstances of the subject, and these factors are within the range judged by the skilled physician or dietitian.
  • the IPP2 or an agonist thereof can be administered by various methods well known in the art. mammal. Preferably, it can be carried out by means of gene therapy.
  • IPP2 or an agonist thereof can be directly administered to a subject by a method such as injection; or, an expression unit carrying an IPP2 or an agonist thereof (such as an expression vector or a virus, etc.) can be delivered to a target by a certain route.
  • Point and expression of active IPP2 or an agonist thereof will depend, inter alia, on the type of agonist described, which are well known to those skilled in the art.
  • a gene encoding IPP2 or an agonist thereof, or a vector carrying the gene can be introduced into a target cell or a target tissue by a conventional method to effect expression of an IPP2 protein or an agonist thereof.
  • the target tissue is a site of inflammation.
  • the human phosphatase inhibitor IPP2 was first revealed to significantly inhibit inflammatory factors. Therefore, human phosphatase inhibition
  • the factor IPP2 itself can be used to prepare a composition for inhibiting inflammatory factors, or the human phosphatase inhibitor IPP2 can be used as a target for drug screening for screening for substances that inhibit inflammatory factors by promoting their activity.
  • the invention is further illustrated below in conjunction with specific embodiments. It is to be understood that the examples are merely illustrative of the invention and are not intended to limit the scope of the invention.
  • RNA from human bone marrow stromal cells was extracted with Trizol reagent (Invitrogen).
  • the poly(A) mRNA is then isolated from total RNA.
  • the cDNA fragment was inserted into the multiple cloning site of the vector by SuperScriptll cloning kit (Invitrogen), and DH5oc bacteria were transformed to form a cDNA plasmid library.
  • the sequence of the 5' end of the randomly selected clone was determined by the dideoxy method. Comparing the determined cDNA sequence with the existing public DNA sequence database revealed that the DNA sequence of one cDNA clone was a new full-length cDNA.
  • the DNA sequence contained in the new clone was bidirectionally determined by synthesizing a series of primers.
  • This protein is called human bone marrow stromal cell-derived type 1 phosphatase inhibitor IPP2
  • its coding gene is called human bone marrow stromal cell-derived type 1 phosphatase inhibitor IPP2 gene.
  • the sequence SEQ ID NO: l is 1637 bp in length and comprises a 234 bp 5' non-coding region and a 1052 bp 3' non-coding region encoding a polypeptide of 116 amino acids.
  • the molecular weight of the unglycosylated mature molecule is about 39 kD.
  • RNA 5 g of total cellular RNA was mixed with lg Oligo-dT 12 - 18 for reverse transcription. The reverse transcription system was 20 ⁇ l, and after the reaction was completed, 80 ⁇ l ddH 2 O was added for dilution. PCR amplification of IPP2 The primers used are as follows:
  • Sense primer 5 TTGCCGTGCCTGTATTCCA (SEQ ID NO: 3),
  • Antisense primer 5 GAATCGGAGGTGGTGTTTGT (SEQ ID NO: 4),
  • ⁇ -actin was used as a positive control.
  • the PCR reaction volume is 50 ⁇ 1, which contains the reverse transcription template 10 ⁇ 1, 0.5mM primer, 0.2mM dNTP and 1U rTaq DNA polymerase (Takara).
  • the amplification parameters are 95 °C for 15 seconds, 57 °C for 30 seconds, 72 °. C 30 seconds, extended for 10 minutes at 72 °C after 28 cycles.
  • the PCR product was initially confirmed by 1.5% agarose gel electrophoresis. The results of DNA sequence analysis indicated that the DNA sequence of the PCR product was identical to that of 412-882 shown in SEQ ID NO: 1.
  • IPP2 was expressed in THP-1, K562, TF-1, Molt-4, Daudi, Hela, A549, HT-29, U251 tumor cells (all of which were obtained from ATCC), as shown in Figure 1A. And Figure 1B. Moreover, IPP2 is also expressed in the fetal brain, fetal hippocampus, and fetal cerebellum, as shown in Figure 1C.
  • Example 3 Northern blot analysis of human IPP2
  • Northern blotting was performed as follows: The filter to be tested was placed in 10 ml of a pre-warmed hybridization solution at 68 ° C, pre-hybridized in a hybridization oven (Bellco) at 68 ° C for 30 minutes; the labeled cDNA probe was 95 Denature at ⁇ 100 °C for 2 to 5 minutes, add rapidly to the ice and add the hybridization solution (final concentration of cDNA probe is 2 ⁇ 10ng/ml or l ⁇ 2 X 10 6 cpm/ml), mix well, at 68° C hybridization for 2 hours.
  • Bellco hybridization oven
  • the filter was rinsed several times with 2xSSC, 0.05% SDS at room temperature, followed by shaking for 30 to 40 minutes, during which the lotion was changed several times. Subsequently, it was rinsed with 0. 1xSSC, 0.1% SDS at 50 ° C for 20 to 40 minutes. Finally, the filter was wrapped in a plastic wrap and exposed to X-ray film at -70 ° C for 24 to 48 hours.
  • IPP2 was expressed in different degrees in normal tissues such as liver, testis, skeletal muscle, heart and spleen (2.0 kb), indicating that IPP2 protein is a specific expressed protein, see Figure 2A. Moreover, IPP2 is also expressed to some extent in fetal brain and fetal liver, as shown in Figure 2B.
  • the full-length plasmid DNA of Example 1 was used as a template, and amplification was carried out using PCR primers at the 5' and 3' ends of the sequence below to obtain human IPP2 DNA as an insert.
  • the 5'-end oligonucleotide primer sequence used in the PCR reaction is:
  • the primer contains a restriction endonuclease of BamH I restriction endonuclease, followed by a partial coding sequence of human IPP2;
  • the 3' primer sequence is:
  • This primer contains the EcoR I restriction endonuclease cleavage site, translational terminator and partial coding sequence of human IPP2.
  • the obtained PCR product was purified, digested with BamH I/EcoR I and then recombined with plasmid pGEM-3ZF (Promega) according to a conventional method and transformed into competent E. coli BL21, and the positive clone was picked, identified, purified and sequenced (ABI company Model 377 Sequencer, BigDye Terminator Kit, PE).
  • the correct sequence of human IPP2 cDNA EcoR I was cloned into the expression vector pGEX-2T (Pharmacia) to form vector pGEX-2T-IPP2, which was then transformed into E. coli BL21. Positive clones were identified by BamH I/EcoR I digestion and the products were analyzed by 0.8% agarose gel electrophoresis. It was confirmed by sequencing that the designed IPP2 coding sequence was inserted.
  • the positive BL21 clone expressing IPP2 was inoculated into 100 ml 2xYTA medium, and cultured at 37 ° C, 300 rpm, shaking 12-151 °, 1:10 diluted in pre-warmed 2 ⁇ butyl medium and shaking culture 1.5111", adding lOOmM IPTG to O.
  • lmM was induced at 30 ° C for 2-6 hr, 5,000 g at 4 ° C for 10 min to remove the supernatant, and placed on ice with 50 ml of lxPBS (0.14 M NaCl, 2.7 mM KC1, lO.
  • the recombinant protein human IPP2 obtained in Example 4 was used to immunize an animal to produce an antibody, as follows.
  • the recombinant molecules are separated by chromatography and used. Separation can also be performed by SDS-PAGE gel electrophoresis, and the electrophoresis band is excised from the gel and emulsified with an equal volume of complete Freund's adjuvant.
  • Mice were intraperitoneally injected with 50-100 ⁇ g/0.2 ml of the emulsified protein. After 14 days, mice were intraperitoneally injected with a dose of 50-100 g/0.2 ml with the same antigen emulsified with incomplete Freund's adjuvant to boost the immunization.
  • Example 2 using the full-length plasmid DNA of Example 1 as a template, amplification was carried out using PCR oligonucleotide primers at the 5' and 3' ends of the sequence below to obtain human IPP2 DNA as an insert.
  • the 5' oligonucleotide primer sequence used in the PCR reaction was: 5 '-CAGAATTCATGGAGCCCAACAGTCCCA-3, (SEQ ID NO: 7). This primer contains EcoR
  • restriction endonuclease site of restriction endonuclease which is followed by a translation initiator and a partial coding sequence of human IPP2;
  • the end primer sequence is: 5,- TCAAGCTTGAATGGTCCCGCTGCTCC -3' (SEQ ID NO: 8).
  • This primer contains a restriction endonuclease of Hind III restriction endonuclease and a partial coding sequence of human IPP2.
  • the obtained PCR product was purified, digested with EcoR I/Hind III, and then recombined with plasmid pcDNA 3.1/Myc-His (-) B (Invitrogen) according to a conventional method and transformed into competent E. coli DH5oc, and the positive clone was identified. Purification and sequencing (ABI's Model 377 sequencer, BigDye Terminator kit, PE) was used to form the wild-type eukaryotic expression vector pcDNA 3.1-IPP2 vector (WT;). It was confirmed by sequencing that the designed IPP2 coding sequence was inserted.
  • the pcDNA 3.1-IPP2 vector (WT) plasmid DNA was used as a template, and the PCR primers at the 5' and 3' ends of the sequence were used for PCR point mutation to construct a 40-threonine mutant expression vector CA.
  • the 5' oligonucleotide primer sequence used in the PCR reaction was: 5'-AGAAGACCTGCACCAGCATC -3' (SEQ ID NO: 9).
  • the primer converts the codon ACA of threonine to the codon GCA of lysine;
  • the end primer sequence is: 5, - GATGCTGGTGCAGGTCTTCT -3, (SEQ ID NO: 10).
  • the PCR reaction volume was 50 ⁇ l, including plasmid DNA template 1 ⁇ 1, 0.5 ⁇ bow, 0.2 mM dNTP, and 1U Pyrobest DNA polymerase (Takara).
  • the amplification parameters were 95 °C for 15 seconds, 58 °C for 30 seconds, and 72°. C 30 seconds, 20 cycles and 72 ° C extension for 10 minutes.
  • the PCR product was initially confirmed by 0.8% agarose gel electrophoresis.
  • the obtained PCR product was purified and treated with T4 polynucleotide kinase and phosphoric acid, and blunt-ligated and transformed into competent Escherichia coli DH5oc.
  • the IPP2 expression vector WT and the mutant of Example 6 were transfected into RAW 264.7 cells (ATCC: TIB-71) with LipofectAMINE reagent (Invitrogen), and G418 (Sigma) was sieved stably. Determine the expression of cell lines. 10 6 cells were plated in a 6-well plate, and the cells were attached to the wall and then added with a NO generator, lmM SNP (Sigma) for 24 hours for PI/Anne X inV (BD) staining, and detected by flow cytometry.
  • a NO generator lmM SNP (Sigma) for 24 hours for PI/Anne X inV (BD) staining, and detected by flow cytometry.
  • the IPP2 expression vector WT and the mutant of Example 6 were transfected into RAW 264.7 cells with LipofectAMINE reagent, and G418 was used to screen out stable expression cell lines. 10 6 cells were plated in 6-well plates, and cells were ligated with lug/ml of LPS Sigma for 18 h. The content of IL-6 and TNF in the cell supernatant was quantitatively determined by ELISA, and the main steps were in accordance with the kit instructions (R&D;).
  • the RAW 264. 7 cells transfected with the IPP2 expression vector WT of Example 6 were used as the subject, and the expression of IPP2 in the cells before and after the stimulation of the candidate substance was quantitatively detected, and the antibiotic prepared by the above was used.
  • the human IPP2 antibody was subjected to a hybridization test, and the expression of IPP2 in the cells was determined by detecting the binding strength of the IPP2-IPP2 antibody to each other.
  • Test group RAW 264. 7 cells with candidate substance added, the cells were transfected with IPP2 expression vector WT; control group: RAW 264. 7 cells without candidate substance, the cell was transfected with IPP2 expression vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)

Abstract

La présente invention concerne les utilisations de l'inhibiteur 2 de la protéine phosphatase 1 humaine (IPP2) pour préparer des compositions qui inhibent la sécrétion de facteurs inflammatoires tels que IL-6 et TNFα. Cette invention porte également sur un procédé de recherche de substances qui inhibent la sécrétion des facteurs inflammatoires au moyen de IPP2 en tant que cible pour la recherche de médicaments.
PCT/CN2007/070638 2007-09-05 2007-09-05 Fonctions et utilisations de l'inhibiteur 2 de la protéine phosphatase 1 humaine WO2009030093A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070638 WO2009030093A1 (fr) 2007-09-05 2007-09-05 Fonctions et utilisations de l'inhibiteur 2 de la protéine phosphatase 1 humaine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070638 WO2009030093A1 (fr) 2007-09-05 2007-09-05 Fonctions et utilisations de l'inhibiteur 2 de la protéine phosphatase 1 humaine

Publications (1)

Publication Number Publication Date
WO2009030093A1 true WO2009030093A1 (fr) 2009-03-12

Family

ID=40428444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/070638 WO2009030093A1 (fr) 2007-09-05 2007-09-05 Fonctions et utilisations de l'inhibiteur 2 de la protéine phosphatase 1 humaine

Country Status (1)

Country Link
WO (1) WO2009030093A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027971A2 (fr) 2009-09-01 2011-03-10 주식회사이언메딕스 Vésicules extracellulaires dérivées de la flore intestinale, et procédé de recherche d'un modèle de maladie, d'un vaccin et d'un médicament candidat, et de diagnostic utilisant ce dernier
US8969653B2 (en) 2009-09-01 2015-03-03 Aeon Medix Inc. Extracellular vesicles derived from gram-positive bacteria, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551200A1 (fr) * 1992-01-07 1993-07-14 National University Of Singapore Protéine phosphatase inhibiteur pour l'utilisation en thérapeutique
JPH06316534A (ja) * 1992-01-10 1994-11-15 Kao Kishinmin 治療用のプロテインホスファターゼインヒビター
CN1475501A (zh) * 2002-08-16 2004-02-18 浙江大学免疫学研究所 新型人骨髓基质细胞来源的1型磷酸酶抑制因子，其编码序列及用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551200A1 (fr) * 1992-01-07 1993-07-14 National University Of Singapore Protéine phosphatase inhibiteur pour l'utilisation en thérapeutique
JPH06316534A (ja) * 1992-01-10 1994-11-15 Kao Kishinmin 治療用のプロテインホスファターゼインヒビター
CN1475501A (zh) * 2002-08-16 2004-02-18 浙江大学免疫学研究所 新型人骨髓基质细胞来源的1型磷酸酶抑制因子，其编码序列及用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, XIAOJIAN ET AL.: "Cloning and characterization of novel molecules, hPEBP4 and IPP2, from human bone marrow stromal cells", CHINESE DOCTORAL DISSERTATIONS & MASTER'S THESES FULL-TEXT DATABASE (DOCTOR) MEDICINE AND HEALTH SCIENCES, 2004, pages E072 - 7 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027971A2 (fr) 2009-09-01 2011-03-10 주식회사이언메딕스 Vésicules extracellulaires dérivées de la flore intestinale, et procédé de recherche d'un modèle de maladie, d'un vaccin et d'un médicament candidat, et de diagnostic utilisant ce dernier
US8969653B2 (en) 2009-09-01 2015-03-03 Aeon Medix Inc. Extracellular vesicles derived from gram-positive bacteria, and use thereof
US9201072B2 (en) 2009-09-01 2015-12-01 Aeon Medix Inc. Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same
US9274109B2 (en) 2009-09-01 2016-03-01 Aeon Medix Inc. Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same

Similar Documents

Publication Publication Date Title
EA010741B1 (ru) ПРИМЕНЕНИЕ ПОЛИПЕПТИДОВ ЦИТОКИНА Zcyto ЧЕЛОВЕКА И МЫШИ И АНТИТЕЛ К ДАННЫМ ПОЛИПЕПТИДАМ ДЛЯ ЛЕЧЕНИЯ РАЗЛИЧНЫХ ЗАБОЛЕВАНИЙ
WO2009030093A1 (fr) Fonctions et utilisations de l'inhibiteur 2 de la protéine phosphatase 1 humaine
JP2000500350A (ja) 新規なヒトユビキチン共役酵素
KR20010043090A (ko) 신규인 폴리펩티드, 그 폴리펩티드를 코드화하는 ｃＤＮＡ및 그 용도
WO2001038522A1 (fr) Nouveau polypeptide, histone humaine h2a.21, et polynucleotide codant pour ce polypeptide
EP1180525B1 (fr) Proteine inhibitrice d'activation transcriptionnelle
WO2001038371A1 (fr) Nouveau polypeptide glutamate arnt synthetase 58 d'origine humaine et polycnucleotide codant pour ce polypeptide
RU2772733C2 (ru) Hmgb1 мутанты
JPH11187882A (ja) 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｃＤＮＡ、そのｃＤＮＡからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物
US6908765B1 (en) Polypeptide—human SR splicing factor 52 and a polynucleotide encoding the same
US6919430B1 (en) Polypeptide—human galectin 15 and a polynucleotide encoding the same
US6994996B1 (en) Polypeptide, human vacuolar H+ -ATPase C subunit 42 and polynucleotide encoding it
WO2009030094A1 (fr) Fonction et utilisation d'une nouvelle protéine induisant une apoptose associée aux lysosomes contenant les domaines ph et fyve (lapf)
WO2001031030A1 (fr) Nouveau polypeptide, phosphodiesterase 21 humaine de type acide sphingomyelinase, et polynucleotide codant pour ce polypeptide
WO2001038545A1 (fr) Nouveau polypeptide, acetyle galactosyle transferase 45 humain et polynucleotide codant ce polypeptide
WO2009030084A1 (fr) NOUVELLES FONCTIONS ET UTILISATIONS DE LA PETITE PROTÉINE G HUMAINE DE TYPE ONCOGÈNE RabJ
WO2001019864A1 (fr) Polynucleotides codant pour des nouvelles proteines humaines du recepteur de l'angiotensine ii-1, leur procede de preparation et leur utilisation
WO2001019865A1 (fr) Nouvelle muskeline et ses procedes d'application et de production
WO2001030818A1 (fr) Nouveau polypeptide, proteine de liaison 33 a l'arn, et polynucleotide codant pour ce polypeptide
WO2001031001A1 (fr) Nouveau polypeptide, facteur auxiliaire 28 du facteur de demarrage de la traduction, et polynucleotide codant pour ce polypeptide
WO2002022676A1 (fr) Proteine garante de longevite, sa sequence de codage et ses utilisations
WO2001038369A1 (fr) Nouveau polypeptide porteur tricarboxylate 39 du rat- et polynucleotide codant ledit polypeptide
WO2001030840A1 (fr) Nouveau polypeptide, une proteine 57 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001032863A1 (fr) Nouveau polypeptide, proteine humaine 12 associee a l'apoptose (sag), et polynucleotide codant pour ce polypeptide
WO2001038390A1 (fr) Nouveau polypeptide - proteine 25 snare humaine et polynucleotide la codant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07801047

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07801047

Country of ref document: EP

Kind code of ref document: A1